Search defense grants, SBIR/STTR topics, contract notices and public calls together. Select notices across searches, record your next questions, and share a public shortlist with your team.
Applicant-type filters select Grants.gov records only; they do not establish your eligibility. Every search word must appear in the title, notice number, summary or buyer. SBIR/STTR filters select DSIP records; TACFI and RNI select the reviewed public calls. Unknown closing dates remain visible; check the original notice for interim deadlines.
Your decision shortlist
Select up to 12 notices across searches. Add your next question and action, then export a brief for your team. Notes stay in this browser; saving is optional. Shared links contain public notice IDs only.
46 matching records
Showing 26–46. Downloads contain all filtered records.
Grants.govDefense Health Agency Contracting Activity - DHACA · Posted notice
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.• Identifying the most effective…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is a…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports studies that have the potential to make an important contribution to spinal cord injury (SCI) research, patient care and/or quality of life. May focus on any phase of research from basic through translational science, though studies that focus solely on identifying intervention targets are discouraged.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be …
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) supports translational research that will accelerate the movement of promising ideas in spinal cord injury (SCI) research into clinical applications.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an …
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA app…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials.
Distinctive Features:
· The IIRA offers two Funding Levels to support research at different stages and th…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· If developing new drugs or device(s), the research team must include expertise i…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research.…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-impact translational research that will accelerate the movement of promising ideas and/or technologies in trauma care into solutions to maximize casualty survivability, improve patient care closer to the point of injury and/or trauma care guidelines. Preliminary data are required. Research using well-validated animal models is allowed.Distinctive Features:• **NEW for FY26** An investigator may be named as the Principal Investigator (PI) on only one FY26 CRRP TRA application.• R…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct re…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinct…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities.Distinctive Features: • Applied research is defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mecha…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation.Distinctive Features:The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research.Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study.Research should have high potential impact on rare cancers and the pat…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps:Lack of research and clinical resources, including patient tissues, cell and tumor models.Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical find…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to deter…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used.
https://cdmrp.health.mil/pubs/press/2026/terp…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or …
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
ATTENTION: This announcement will be revised regularly to incorporate country specific narratives (Attachment 1 of the announcement) with information vital to the content of application. Potential applicants interested in applying to this announcement should click 'Subscribe' to be notified of future revisions. DoD HIV/AID Prevention Program's (DHAPP) objective, through the PEPFAR program, is to save lives, prevent HIV infections, and accelerate progress toward achieving HIV/AIDS epidemic control and to support the development of interventions and programs in military health systems that address these issues. DHAPP works with militaries of …
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
The USAMRDC’s mission is to provide solutions to medical problems of importance to the American Service Member at home and abroad, as well as to the general public at large. The scope of this effort and the priorities attached to specific projects are influenced by changes in military and civilian medical science and technology (S&T;), operational requirements, military threat assessments, and national defense strategies. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRDC. General information on the USAMRDC can be obtained at https://mrdc.health.mil/.This BAA is inte…
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
The FY23 -FY28 Broad Agency Announcement for Extramural Biomedical Research and Development - HT9425-23-S-SOC1.
Eligibility information: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
Source award range (USD): 750000.00 – 50000000.00. Notice amounts are not an award promise or total program budget.
Check full topic requirements, eligibility and amendments before deciding to respond. Use the opportunity-fit AI workflow and proposal requirements matrix to record evidence and unanswered questions. Calendar downloads are date-only reminders, not official submission times. The optional saved combined shortlist is separate from your funding-notice shortlist.
Defense Tech Base